[go: up one dir, main page]

MA30778B1 - Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques - Google Patents

Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques

Info

Publication number
MA30778B1
MA30778B1 MA31760A MA31760A MA30778B1 MA 30778 B1 MA30778 B1 MA 30778B1 MA 31760 A MA31760 A MA 31760A MA 31760 A MA31760 A MA 31760A MA 30778 B1 MA30778 B1 MA 30778B1
Authority
MA
Morocco
Prior art keywords
adrenergic agonists
sulfonamide derivatives
muscarinic antagonists
disorders
present
Prior art date
Application number
MA31760A
Other languages
English (en)
Inventor
Lyn Howard Jones
Graham Lunn
David Anthony Price
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA30778B1 publication Critical patent/MA30778B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (1) ET DES PROCÉDÉS DE PRÉPARATION DE TELS DÉRIVÉS, LES INTERMÉDIAIRES UTILISÉS DANS LEUR PRÉPARATION, DES COMPOSITIONS QUI LES CONTIENNENT ET LEURS UTILISATIONS. LES COMPOSÉS SELON LA PRÉSENTE INVENTION SONT UTILISABLES DANS DE NOMBREUSES MALADIES, TROUBLES ET AFFECTIONS, EN PARTICULIER LES MALADIES, TROUBLES ET AFFECTIONS INFLAMMATOIRES, ALLERGIQUES ET RESPIRATOIRES.
MA31760A 2006-10-04 2009-04-03 Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques MA30778B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82809906P 2006-10-04 2006-10-04

Publications (1)

Publication Number Publication Date
MA30778B1 true MA30778B1 (fr) 2009-10-01

Family

ID=38947725

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31760A MA30778B1 (fr) 2006-10-04 2009-04-03 Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques

Country Status (25)

Country Link
US (1) US20080090873A1 (fr)
EP (1) EP2074094A1 (fr)
JP (1) JP2010505810A (fr)
KR (1) KR20090050104A (fr)
CN (1) CN101522622A (fr)
AP (1) AP2009004791A0 (fr)
AR (1) AR063118A1 (fr)
AU (1) AU2007303909A1 (fr)
BR (1) BRPI0719270A2 (fr)
CA (1) CA2665385A1 (fr)
CL (1) CL2007002791A1 (fr)
CO (1) CO6180437A2 (fr)
CR (1) CR10700A (fr)
EA (1) EA200900337A1 (fr)
IL (1) IL197244A0 (fr)
MA (1) MA30778B1 (fr)
MX (1) MX2009002209A (fr)
NO (1) NO20090910L (fr)
PE (1) PE20080831A1 (fr)
RS (1) RS20090137A (fr)
TN (1) TN2009000112A1 (fr)
TW (1) TW200823185A (fr)
UY (1) UY30617A1 (fr)
WO (1) WO2008041095A1 (fr)
ZA (1) ZA200901320B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
CN105142673B8 (zh) 2012-12-18 2018-02-16 阿尔米雷尔有限公司 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
ES2836113T3 (es) 2016-12-14 2021-06-24 Beijing Showby Pharmaceutical Co Ltd Clase de compuestos bifuncionales con estructura de sal de amonio cuaternario
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2021505569A (ja) * 2017-12-04 2021-02-18 フリードリヒ−アレクサンダー−ウニヴェルシテート エアランゲン−ニュルンベルク Ｍ２よりもｍ３に対して選択性を有するフルオロフェニル置換ムスカリン受容体リガンド
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (fr) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyle et composes apparentes ayant les activites agoniste du recepteur beta2 adrenergique et antagoniste de recepteur de muscarinic
JP4616264B2 (ja) * 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
GEP20084452B (en) * 2004-01-22 2008-08-10 Pfizer Sulfonamide derivatives for the treatment of diseases
WO2005080375A1 (fr) * 2004-02-13 2005-09-01 Theravance, Inc. Cristalline d'un compose biphenyle
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
WO2008041095A1 (fr) 2008-04-10
MX2009002209A (es) 2009-03-16
CN101522622A (zh) 2009-09-02
CR10700A (es) 2009-04-24
AR063118A1 (es) 2008-12-30
EP2074094A1 (fr) 2009-07-01
ZA200901320B (en) 2010-04-28
PE20080831A1 (es) 2008-06-20
IL197244A0 (en) 2009-12-24
TN2009000112A1 (fr) 2010-08-19
RS20090137A (sr) 2010-06-30
AU2007303909A1 (en) 2008-04-10
BRPI0719270A2 (pt) 2014-03-11
JP2010505810A (ja) 2010-02-25
EA200900337A1 (ru) 2009-10-30
CA2665385A1 (fr) 2008-04-10
US20080090873A1 (en) 2008-04-17
UY30617A1 (es) 2008-05-31
CL2007002791A1 (es) 2008-04-11
TW200823185A (en) 2008-06-01
KR20090050104A (ko) 2009-05-19
NO20090910L (no) 2009-03-24
AP2009004791A0 (en) 2009-04-30
CO6180437A2 (es) 2010-07-19

Similar Documents

Publication Publication Date Title
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA30289B1 (fr) Dérivés d'amines
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA27452A1 (fr) Derives d'indole servant d'agonistes beta-2
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MXPA05013059A (es) Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
MA33768B1 (fr) Triazolopyridines
MA35153B1 (fr) Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants
TNSN06369A1 (fr) Derives de tetrahydronaphtyridine utiles comme ligands du recepteur d'histamine h3
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA29926B1 (fr) Derives de pyrazine
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN07167A1 (fr) Indoles substitues, compositions les contenant, procede de fabrication et utilisation
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
MA29723B1 (fr) Composes